Schumock Glen T, Li Edward C, Suda Katie J, Wiest Michelle D, Stubbings Joann, Matusiak Linda M, Hunkler Robert J, Vermeulen Lee C
Glen T. Schumock, Pharm.D., M.B.A., Ph.D., FCCP, is Professor and Head, Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago, Chicago. Edward C. Li, Pharm.D., M.P.H., BCOP, is Associate Professor, Department of Pharmacy Practice, College of Pharmacy, University of New England, Portland, ME. Katie J. Suda, Pharm.D., M.S., is Research Health Scientist, Department of Veterans Affairs, Center of Innovation for Complex Chronic Healthcare, Edward Hines Jr. VA Hospital, Hines, IL, and Research Associate Professor, University of Illinois at Chicago. Michelle D. Wiest, Pharm.D., BCPS, FASHP, is Vice President, Pharmacy Services, UC Health, Cincinnati, OH, and Clinical Associate Professor, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati. Joann Stubbings, B.S.Pharm., M.H.C.A., is Clinical Associate Professor, Department of Pharmacy Systems, Outcomes and Policy, and Assistant Director, Specialty Pharmacy Services, College of Pharmacy, University of Illinois at Chicago. Linda M. Matusiak, B.A., is Senior Manager, Research Support, IMS Health, Plymouth Meeting, PA. Robert J. Hunkler, M.B.A., is Director, Professional Relations, IMS Health. Lee C. Vermeulen, B.S.Pharm., M.S., FCCP, FFIP, is Director, Center for Clinical Knowledge Management, UW Health, Madison, WI, and Clinical Professor, School of Pharmacy, University of Wisconsin, Madison.
Am J Health Syst Pharm. 2015 May 1;72(9):717-36. doi: 10.2146/ajhp140849.
An analysis of trends in U.S. pharmaceutical spending is presented, including projections for drug expenditures in nonfederal hospital and clinic settings in 2015.
Prescription drug expenditure data through September 2014 were obtained from the IMS Health National Sales Perspectives database and were analyzed descriptively. Other factors that may influence prescription spending in hospitals and clinics in 2015, including new drug approvals and patent expirations, were analyzed. Expenditure projections were based on a combination of quantitative and qualitative analyses and expert opinion.
Total prescription sales for the 12 months ending September 30, 2014, were $360.7 billion, 12.2% higher than during the previous 12 months. With $6.6 billion in expenditures in the first 9 months of 2014, sofosbuvir topped the overall list of drugs based on sales, followed by aripiprazole and insulin glargine. Pharmaceutical spending by clinics and nonfederal hospitals rose by 13.3% and 4.0%, respectively. For the first 9 months of 2014, the top drugs based on expenditures were infliximab, pegfilgrastim, and epoetin alfa in clinics and infliximab, rituximab, and pegfilgrastim in hospitals. Specialty drugs continued to constitute an increasing portion of drug expenditures and will contribute to higher expenditures in 2015.
Growth in U.S. prescription drug expenditures is expected to continue to increase in 2015. The projected increases in total drug expenditures are 7-9% across all settings, 12-14% in clinics, and 5-7% in hospitals. Health-system pharmacy leaders should carefully examine their own local drug utilization patterns to determine their own organization's anticipated spending in 2015.
对美国药品支出趋势进行分析，包括对2015年非联邦医院和诊所环境下药品支出的预测。
通过IMS Health国家销售视角数据库获取截至2014年9月的处方药支出数据，并进行描述性分析。分析了其他可能影响2015年医院和诊所处方药支出的因素，包括新药批准和专利到期情况。支出预测基于定量和定性分析以及专家意见的综合。
截至2014年9月30日的12个月内，处方药总销售额为3607亿美元，比前12个月高出12.2%。索非布韦在2014年前9个月支出66亿美元，在基于销售额的药品总体排名中位居榜首，其次是阿立哌唑和甘精胰岛素。诊所和非联邦医院的药品支出分别增长了13.3%和4.0%。2014年前9个月，基于支出的诊所前三大药品为英夫利昔单抗、培非格司亭和阿法依泊汀，医院为英夫利昔单抗、利妥昔单抗和培非格司亭。专科药物在药品支出中所占比例持续增加，并将导致2015年支出更高。
预计2015年美国处方药支出将继续增长。所有环境下药品总支出预计增长7 - 9%，诊所为12 - 14%，医院为5 - 7%。卫生系统药房负责人应仔细审查自身当地的药品使用模式，以确定其所在机构2015年的预期支出。
